What is exteRNA?
Founded in 2024, exteRNA operates at the forefront of the biotechnology industry, specializing in the development of novel small molecule therapeutics. The company's core competency lies in its ability to modulate RNA processing pathways, a critical area of focus for treating diseases that have historically been considered undruggable. By utilizing a team of seasoned scientists and industry veterans, exteRNA is bridging the gap between fundamental research and clinical application. The company's market position is bolstered by its strategic alignment with leading research institutions and venture capital firms that prioritize deep-tech innovation in the life sciences space.
How much funding has exteRNA raised?
exteRNA has raised a total of $22M across 2 funding rounds:
Angel/Seed
$11M
Angel/Seed
$11M
Angel/Seed (2024): $11M with participation from Hostplus, Tin Alley Ventures, WEHI, and IP Group
Angel/Seed (2024): $11M led by Tin Alley Ventures, Hostplus, IP Group, and WEHI
Key Investors in exteRNA
Tin Alley Ventures
A specialized fund focused on deep tech startups and life sciences spinouts, leveraging research intellectual property from the University of Melbourne.
IP Group
An investment firm that collaborates with universities and corporate partners to transform scientific innovation into high-impact, scalable businesses.
WEHI
Australia's oldest medical research institute, providing deep scientific expertise and institutional support for breakthrough biomedical ventures.
What's next for exteRNA?
With the recent capital deployment, exteRNA is expected to scale its laboratory operations and advance its lead candidates toward preclinical milestones. The strategic focus will likely remain on validating its proprietary platform, which is designed to identify and optimize small molecules that interact with RNA structures. As the company transitions from its initial development phase, the focus will shift toward establishing robust intellectual property portfolios and exploring potential partnerships with larger pharmaceutical entities. The current funding environment suggests that exteRNA is well-positioned to navigate the complexities of drug development, provided it maintains its current pace of scientific discovery and operational execution.
See full exteRNA company page
